Drug Trial Radar · NCT03948620
Macrolide in Pregnancy and Adverse Child Outcomes
Last checked: Nov 19, 2026Latest source record: May 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
726,274
Actual
Start
Jan 1, 1990
Primary completion
Jun 30, 2016
Study completion Jun 30, 2016
Sponsor
- Lead sponsor
- Institute of Child HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 14, 2019
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Over the last 20 years, concerns have been raised about rare but serious adverse outcomes associated with macrolide use during pregnancy. The strongest evidence comes from a large randomised controlled trial (RCT, ORACLE Child Study II) of women with spontaneous preterm labour (SPL), which reported an increased risk of cerebral palsy in children whose mothers received erythromycin compared with no erythromycin. A recent systematic review on macrolides prescription during pregnancy showed consistent associations with miscarriage, and less consistent associations with adverse child outcomes such as congenital malformations, cerebral palsy and epilepsy. In this study, the investigators will evaluate associations between macrolide antibiotics prescription during pregnancy and a range of adverse child outcomes. The investigators compare children whose mothers were prescribed an only monotherapy of macrolides or penicillins during pregnancy (from 5 gestational week (GW) to delivery and by trimesters). The investigators estimate the risk ratios of major malformation (overall and five system-specific) and hazard ratios of four neurodevelopmental disorders (cerebral palsy, epilepsy, attention-deficit/hyperactivity disorder, and autism spectrum disorder) with control for potential confounders. The associations will also be examined by subtype of macrolides and treatment duration. Mother-child pairs will be analysed in a cohort selected from the UK Clinical Practice Research Database (CPRD) between 1990 and 2016.
Conditions
- Infection
Interventions
MacrolidesDrug
Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.
PenicillinsDrug
The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of major malformation overallTime frame: From birth up to 4 years after birth.
- Number of cardiovascular malformationTime frame: From birth up to 4 years after birth.
- Number of nervous system malformationTime frame: From birth up to 4 years after birth.
- Number of gastrointestinal system malformationTime frame: From birth up to 4 years after birth.
- Number of genital malformationTime frame: From birth up to 4 years after birth.
- Number of urinary malformationTime frame: From birth up to 4 years after birth.
- Rate of cerebral palsyTime frame: From birth up to 15 years after birth.
- Rate of epilepsyTime frame: From birth up to 15 years after birth.
- Rate of attention-deficit/hyperactivity disorder (ADHD)Time frame: From birth up to 15 years after birth.
- Rate of autism spectrum disorder (ASD)Time frame: From birth up to 15 years after birth.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.